All hedge funds or institutions that manage over $100M are required by the SEC to file quarterly reports on their holdings.
These reports are called 13F reports. However, the filings are required
the following quarter
from the reporting period,
which means that by the time the filing is made (and we see them), the information could be five months old.
For funds
with long term positions that make few trades, the holdings might closely resemble their current holdings, even after several months. However, for funds that have high turnover,
the holdings data we see might differ significantly from their current holdings. Institutions are required to report CALL and PUT options, and those positions
are identified in the table. However, they are not required to report short positions.
Click the link icon to see the full transaction history.
Upgrade
to unlock premium data and export to Excel 
.
| Security |
Imputed
Share Price |
Prev
Shares |
Current
Shares |
Change
(Percent) |
Prev Value
(USD x1000) |
Current Value
(USD x1000) |
Change
(Percent) |
|---|
| OYST / Oyster Point Pharma Inc
|
|
|
|
|
|
|
|
| CTIC / CTI BioPharma Corp
|
|
|
|
|
|
|
|
| COUR / Coursera, Inc.
|
|
|
|
|
|
|
|
| VTGN / Vistagen Therapeutics, Inc.
|
|
|
|
|
|
|
|
| GLBE / Global-E Online Ltd.
|
|
|
|
|
|
|
|
| US0846561076 / Berkshire Grey, Inc.
|
|
|
|
|
|
|
|
| HOOD / Robinhood Markets, Inc.
|
|
|
|
|
|
|
|
| NN / NextNav Inc.
|
|
|
|
|
|
|
|
| EAR / Eargo, Inc.
|
|
|
|
|
|
|
|
| IVA / Inventiva S.A. - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
| LUMO / Lumos Pharma, Inc.
|
|
|
|
|
|
|
|
| AKUS / Akouos Inc
|
|
|
|
|
|
|
|
| MEIP / MEI Pharma, Inc.
|
|
|
|
|
|
|
|
| AVEO / AVEO Pharmaceuticals Inc
|
|
|
|
|
|
|
|
| BHG / Bright Health Group, Inc.
|
|
|
|
|
|
|
|
| PANW / Palo Alto Networks, Inc.
|
|
|
|
|
|
|
|
| STSA / Satsuma Pharmaceuticals Inc
|
|
|
|
|
|
|
|
| SVRA / Savara Inc.
|
|
|
|
|
|
|
|
| VRNA / Verona Pharma plc - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
| NKTX / Nkarta, Inc.
|
|
|
|
|
|
|
|
| CRSP / CRISPR Therapeutics AG
|
|
|
|
|
|
|
|
| XERS / Xeris Biopharma Holdings, Inc.
|
|
|
|
|
|
|
|
| MIMO / Airspan Networks Holdings Inc.
|
|
|
|
|
|
|
|
| NET / Cloudflare, Inc.
|
|
|
|
|
|
|
|
| BILL / BILL Holdings, Inc.
|
|
|
|
|
|
|
|
| IMRA / Bitwise Funds Trust - Bitwise MARA Option Income Strategy ETF
|
|
|
|
|
|
|
|
| MILE / Metromile Inc
|
|
|
|
|
|
|
|
| PHAS / PhaseBio Pharmaceuticals Inc
|
|
|
|
|
|
|
|
| LXRX / Lexicon Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| GNCA / Genocea Biosciences Inc
|
|
|
|
|
|
|
|
| BDTX / Black Diamond Therapeutics, Inc.
|
|
|
|
|
|
|
|
| RYTM / Rhythm Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| BZFD / BuzzFeed, Inc.
|
|
|
|
|
|
|
|
| AKTX / Akari Therapeutics, Plc - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
| INZY / Inozyme Pharma, Inc.
|
|
|
|
|
|
|
|
| AFMD / Affimed N.V.
|
|
|
|
|
|
|
|
| GERN / Geron Corporation
|
|
|
|
|
|
|
|
| OBSV / ObsEva SA.
|
|
|
|
|
|
|
|
| DMYI.U / dMY Technology Group, Inc. III Units, each consisting of one share of Class A common stock and one-f
|
|
|
|
|
|
|
|
| TCON / TRACON Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| MRKR / Marker Therapeutics, Inc.
|
|
|
|
|
|
|
|
| RPHM / Reneo Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| GLYC / GlycoMimetics, Inc.
|
|
|
|
|
|
|
|
| UTRS / Minerva Surgical, Inc.
|
|
|
|
|
|
|
|
| CSBR / Champions Oncology, Inc.
|
|
|
|
|
|
|
|
| CVRX / CVRx, Inc.
|
|
|
|
|
|
|
|
| GLUE / Monte Rosa Therapeutics, Inc.
|
|
|
|
|
|
|
|
| AUPH / Aurinia Pharmaceuticals Inc.
|
|
|
|
|
|
|
|
| SYBX / Synlogic, Inc.
|
|
|
|
|
|
|
|
| UP / Wheels Up Experience Inc.
|
|
|
|
|
|
|
|
| ADXN / Addex Therapeutics Ltd - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
| ACLX / Arcellx, Inc.
|
|
|
|
|
|
|
|
| SNTI / Senti Biosciences, Inc.
|
|
|
|
|
|
|
|
| MIRM / Mirum Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| ALLK / Allakos Inc.
|
|
|
|
|
|
|
|
| RGLS / Regulus Therapeutics Inc.
|
|
|
|
|
|
|
|
| DM / Desktop Metal, Inc.
|
|
|
|
|
|
|
|
| TRVI / Trevi Therapeutics, Inc.
|
|
|
|
|
|
|
|
| ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
